Elsevier

Clinics in Chest Medicine

Volume 25, Issue 3, September 2004, Pages 593-613
Clinics in Chest Medicine

Pulmonary alveolar proteinosis

https://doi.org/10.1016/j.ccm.2004.04.002Get rights and content

Section snippets

Medical history

Based on several analyses of published case reports and case series that together included more than 400 patients, the common clinical features of patients with PAP are relatively well established [1], [8], [9], [10], [11]. Although the diagnosis has been reported at all ages, a patient who has PAP is typically a previously healthy adult of median age 39 years who describes a history of slowly progressive dyspnea, with these symptoms being present for a median of 7 months. There is a wide range

Differential diagnosis

The differential diagnosis of an adult who has PAP is wide, because the clinical presentation of this syndrome is nonspecific [11], [28]. Although the adult age group excludes congenital PAP as a possibility, acquired PAP occasionally can be secondary to underlying hematopoietic malignancy [5], [29], intrinsic or iatrogenic immunodeficiency disorders [30], [31], lysinuric protein intolerance [32], acute silicosis, and other industrial inhalational syndromes [33].

On first presentation, acquired

Algorithm for investigation

The diagnostic evaluation of a patient with possible PAP begins with a clinical and occupational history and physical examination that focuses on exercise tolerance and exclusion of cardiac disease or systemic disorders, such as sepsis, vasculitis, and malignancy. Blood and differential leukocyte counts help to detect any underlying hematopoietic malignancy, and blood chemistry tests, including renal and liver function assessment, help detect other systemic disorders. Moderately elevated LDH

Therapeutic lung lavage

Physical removal of excess alveolar surfactant material by repeated segmental flooding with saline was first shown to be beneficial in 1960. Modern whole lung lavage using general anesthesia and single lung ventilation via a double lumen endotracheal tube has been standard therapy for several decades in symptomatic patients. This procedure usually is fairly well tolerated, with significant clinical, physiologic, and radiologic improvements expected in up to 84% of cases after the first lavage

Outcome

Deaths directly related to PAP usually have involved respiratory failure (72%) or uncontrolled infection (18%), and most of these events occur within 1 year of diagnosis. Survival prospects for patients who have PAP seem to have improved consistently in the four decades since the condition was first described, such that survival rates approach 100% for cases reported within the last decade [1]. Spontaneous resolution has been reported in a small number of patients, and it seems likely that the

Discovery of the role of granulocyte-macrophage colony-stimulating factor

GM-CSF was chemically purified in the late 1970s [41], and in 1984 it was one of the first human cytokines to be cloned [42]. It was an intense focus of clinical and laboratory investigation through the 1980s and 1990s because of its potent capacity to stimulate the proliferation and differentiation of neutrophilic and monocyte/macrophage lineage hematopoietic cells in vitro, an action that had remained unexplained since its recognition in 1964 [43]. This capacity provides the basis for its

Gene-targeted mice that lack granulocyte-macrophage colony-stimulating factor

In 1994, two independent publications described the creation and analysis of animals that lack GM-CSF (GM-CSF−/−) [59], [60]. The phenotype was identical, with normal viability and apparently normal fertility [61] and normal steady-state hematopoiesis. The dominant abnormality, not found in GM-CSF+/− animals, was “alveolar-proteinosis”–like lung pathology with surfactant accumulation, which manifested as early as 4 to 8 weeks of age and was associated with an increased frequency of pulmonary

Quantification of surfactant protein and lipid abnormalities

The healthy alveolar surface is lined by a thin liquid layer of surfactant, which lowers its surface tension and serves to stabilize alveoli against collapse [66]. Pulmonary surfactant is structurally heterogeneous complex lipid-protein mixture rich in phospholipids [67], [68], [69]. It is composed of 90% to 95% lipid by mass, predominantly di-saturated forms of phosphatidylcholine (SatPC) (approximately 45%), such as dipalmitoylphosphatidylcholine (DPPC), unsaturated PC (approximately 20%),

Surfactant metabolism and kinetic studies

The surfactant lipids and individual proteins are maintained in dynamic equilibrium through incompletely understood regulatory mechanisms that control synthesis, recycling, and catabolism in a coordinated fashion at the whole lung level [82], [83], [84], [85], [86], [87]. Type II alveolar cells, with a large intracellular storage pool of surfactant within their lamellar bodies, are the sole source of surfactant lipid production, whereas type II cells and Clara cells can produce SPs [85], [88].

Phenotypic and functional studies of lung macrophages

Lung macrophages—alveolar and interstitial—are a critical component of immunologic defense of the lung and provide a pivotal link between the innate and acquired immune systems [7], [94]. They are derived from bone marrow (BM) monocyte precursors [95], [96] and have some limited local proliferative capacity [96], but they are responsive in vitro to M-CSF [97], GM-CSF [97], [98], [99], and IL-3 [100]. The effects of these cytokines vary, however, with differential gene expression and

Bone marrow transplantation

Transplantation of wild-type bone marrow cells into irradiated βc−/− recipients resulted in morphologic clearance of surfactant [126], [127]. BAL cellularity and macrophage morphology were normalized and BAL protein levels were corrected. Several abnormalities persisted, however, including focal alveolar macrophage aggregates, periluminal lymphocytic infiltration, and limited areas of fibrosis. Even at 6 months after transplantation, dynamic pulmonary compliance, a measure of lung

Granulocyte-macrophage colony-stimulating factor antibodies and new diagnostic tests

Most reported serologic tests for PAP are based on small series of patients and lack specificity. No specific marker for the serologic diagnosis of PAP was available until the recent discovery of the autoantibody against GM-CSF. The discovery of this antibody provided the explanatory link between the pulmonary phenotype in GM-CSF−/− mice and patients with PAP.

Role of granulocyte-macrophage colony-stimulating factor in alveolar macrophage development and function

Alveolar macrophages from GM-CSF−/− mice do not express the differentiation-inducing transcription factor, PU.1. Retroviral-mediated PU.1 expression in cultured GM-CSF−/− alveolar macrophages corrects most of the observed defects, including SP catabolism. GM-CSF plays a critical role in surfactant homeostasis by acting locally in the murine lung and stimulating alveolar macrophage terminal differentiation.

GM-CSF in the lung also is likely to be critical for surfactant homeostasis in humans, as

Granulocyte-macrophage colony-stimulating factor as therapy for pulmonary alveolar proteinosis

Although the enormous body of data that clarified the pathogenetic link between GM-CSF neutralizing antibodies and PAP was not known at the time, clinical trials that explored the therapeutic role of GM-CSF commenced in the mid 1990s. The first treated patient in the world responded favorably, with improved oxygenation, which prompted early reporting of this new phenomenon [157]. At the completion of this initial study using 5 μg/kg/day subcutaneous GM-CSF with the potential for later dose

Acknowledgements

The authors wish to thank the following investigators, who made substantial and critical contributions to the work performed in Dr. Nakata's laboratory described herein: Dr. Kanji Uchida, Dr. Emi Hamano, and Dr. Inoue's clinical laboratory described herein: Dr. Toru Arai, Ms. Miho Oka, Ms. Eri Kurokawa, and Ms. Yukiko Hashimoto.

First page preview

First page preview
Click to open first page preview

References (171)

  • S.L. Cheng et al.

    Pulmonary alveolar proteinosis: treatment by bronchofiberscopic lobar lavage

    Chest

    (2002)
  • A.W. Burgess et al.

    Purification and properties of colony-stimulating factor from mouse lung-conditioned medium

    J Biol Chem

    (1977)
  • J.O. Armitage

    Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor

    Blood

    (1998)
  • C.A. Evans et al.

    Identification of primary structural features that define the differential actions of IL-3 and GM-CSF receptors

    Blood

    (2002)
  • P.D. Carr et al.

    Structure of the complete extracellular domain of the common β subunit of the human GM-CSF, IL-3, and IL-5 receptors reveals a novel dimer configuration

    Cell

    (2001)
  • A. Miyajima et al.

    Receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3, and interleukin-5

    Blood

    (1993)
  • N. Stahl et al.

    The alphas, betas, and kinases of cytokine receptor complexes

    Cell

    (1993)
  • Y. Zhao et al.

    The amino-terminal portion of the JAK2 protein kinase is necessary for binding and phosphorylation of the granulocyte-macrophage colony-stimulating factor receptor βc chain

    J Biol Chem

    (1995)
  • S.E. Doyle et al.

    Characterization of the role of the human granulocyte-macrophage colony-stimulating factor receptor α subunit in the activation of JAK2 and STAT5

    Blood

    (1998)
  • K. Okuda et al.

    Signaling functions of the tyrosine residues in the βc chain of the granulocyte-macrophage colony-stimulating factor receptor

    Blood

    (1997)
  • Y. Shibata et al.

    GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1

    Immunity

    (2001)
  • R. Nishinakamura et al.

    Mice deficient for the IL-3/GM-CSF/IL-5 βc receptor exhibit lung pathology and impaired immune response, while βIL3 receptor-deficient mice are normal

    Immunity

    (1995)
  • J. Goerke

    Pulmonary surfactant: functions and molecular composition

    Biochim Biophys Acta

    (1998)
  • M. Hallman et al.

    Phosphatidylglycerol in lung surfactant. III. Possible modifier of surfactant function

    J Lipid Res

    (1976)
  • R.J. Mason et al.

    Regulatory mechanisms of surfactant secretion

    Biochim Biophys Acta

    (1998)
  • M. Ikegami et al.

    Surfactant protein metabolism in vivo

    Biochim Biophys Acta

    (1998)
  • B.D.M. Chen et al.

    Interleukin-3 (IL-3) stimulates the clonal growth of pulmonary alveolar macrophage of the mouse: role of IL-3 in the regulation of macrophage production outside the bone marrow

    Blood

    (1988)
  • J.F. Seymour et al.

    Pulmonary alveolar proteinosis: progress in the first 44 years

    Am J Respir Crit Care Med

    (2002)
  • I. Ben-Dov et al.

    Pulmonary alveolar proteinosis in Israel: ethnic clustering

    Isr Med Assoc J

    (1998)
  • J.A. Whitsett et al.

    Hydrophobic surfactant proteins in lung function and disease

    N Engl J Med

    (2002)
  • S. Ladeb et al.

    Secondary alveolar proteinosis in cancer patients

    Support Care Cancer

    (1996)
  • S.H. Rosen et al.

    Pulmonary alveolar proteinosis

    N Engl J Med

    (1958)
  • B.C. Trapnell et al.

    GM-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense

    Annu Rev Physiol

    (2002)
  • H. Asamoto et al.

    Primary pulmonary alveolar proteinosis: clinical observation of 68 patients in Japan

    Nihon Kyobu Shikkan Gakkai Zasshi

    (1995)
  • L.S. Goldstein et al.

    Pulmonary alveolar proteinosis: clinical features and outcomes

    Am J Respir Crit Care Med

    (1997)
  • E.D. Chan et al.

    Pulmonary alveolar proteinosis

  • P.L. Shah et al.

    Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis

    Thorax

    (2000)
  • C.B. Sherter et al.

    Case records of the Massachusetts General Hospital: weekly clinicopathological exercises. Case 2–2001: a 42-year-old woman with acute worsening of chronic dyspnea and cough

    N Engl J Med

    (2001)
  • E. Briens et al.

    Pulmonary alveolar proteinosis

    Rev Mal Respir

    (2002)
  • S.M. Arcasoy et al.

    Images in clinical medicine: pulmonary alveolar proteinosis

    N Engl J Med

    (2002)
  • J.M. Holbert et al.

    CT features of pulmonary alveolar proteinosis

    AJR Am J Roentgenol

    (2001)
  • T. Johkoh et al.

    Crazy-paving appearance at thin-section CT: spectrum of disease and pathologic findings

    Radiology

    (1999)
  • S.E. Rossi et al.

    Crazy-paving pattern at thin-section CT of the lungs: radiologic-pathologic overview

    Radiographics

    (2003)
  • B.C. Trapnell et al.

    Pulmonary alveolar proteinosis

    N Engl J Med

    (2003)
  • J.F. Seymour et al.

    Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis

    Thorax

    (2003)
  • Y. Honda et al.

    Pulmonary surfactant protein D in sera and bronchopulmonary lavage fluid

    Am J Respir Crit Care Med

    (1995)
  • I.R. Doyle et al.

    Serum surfactant protein-A levels in patients with acute cardiogenic pulmonary edema and adult respiratory distress syndrome

    Am J Respir Crit Care Med

    (1995)
  • I.R. Doyle et al.

    Surfactant proteins-A and -B are elevated in plasma of patients with acute respiratory failure

    Am J Respir Crit Care Med

    (1997)
  • C.G. De Pasquale et al.

    Prolonged alveolocapillary barrier damage after acute cardiogenic pulmonary edema

    Crit Care Med

    (2003)
  • K. Iyonaga et al.

    Elevated bronchoalveolar concentrations of MCP-1 in patients with pulmonary alveolar proteinosis

    Eur Respir J

    (1999)
  • Cited by (0)

    Thiswork was supported by a grant-in-aid for translational research, Japanese Ministry of Labor (H114-trans-014).

    View full text